168 Views
Monday Poster Session
Category: IBD
Shiv Gandhi, MD
Tufts University Medical Center
Boston, MA, United States
MS-IBD | IBD | OR | p | |
n | 28 | 112 | ||
Crohn's Disease (%) | 14 (50) | 55 (49.1) | ||
Ulcerative Colitis (%) | 14 (50) | 57 (50.9) | ||
Age (SD) | 51.7 (11.8) | 49 (13.5) | 0.291 | |
Thiopurine (%) | 9 (32.1) | 59 (52.7) | 0.423 | 0.059 |
Anti-TNF (%) | 2 (7.1) | 55 (49.1) | 0.08 | < 0.005 |
Natalizumab (%) | 7 (25) | 2 (1.8) | 18.33 | < 0.005 |
Anti-CD20 (%) | 6 (21.4) | 0 | Inf | < 0.005 |
Frequency of Surgery (%) | 6 (21.4) | 31 (27.7) | 0.59 | 0.634 |